Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can present as an
isolated skin disease or as a manifestation within the spectrum of systemic lupus …

Through this systematic literature review, we assembled evidence to inform the EULAR
recommendations for the non-pharmacological management of systemic lupus …

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with
heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed …

Objective To develop evidence-based recommendations for the non-pharmacological
management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods …

Plasmacytoid dendritic cells (pDC s) represent a specialized dendritic cell population that
exhibit plasma cell morphology, express CD 4, CD 123, blood‐derived dendritic cell antigen …

Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, follows a
chronic disease course, punctuated by flares. Disease flares often occur without apparent …

Cutaneous lupus erythematosus (CLE) is a photosensitive autoimmune disease
characterized by a strong type I IFN-associated inflammation. Keratinocytes are known to …

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that
represents a prodigious challenge of diagnosis and treatment. In 2019, under the leadership …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of
patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous …